Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pruritus Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

NCT03617536
View directory record Official record
Conditions
Chronic Kidney Diseases, Pruritus
Interventions
CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
60
States / cities
Birmingham, Alabama • Florence, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Phase 4 Interventional

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

NCT05314621
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
olopatadine hydrochloride ophthalmic solution 0.7%), Fluticasone Propionate, Tears Naturale, Saline nasal spray
Drug
Lead sponsor
Andover Research Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Phase 1Phase 2 Interventional

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

NCT06162728
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Briquilimab, Placebo
Drug · Other
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 21, 2026, 2:22 PM EDT
Recruiting Phase 2 Interventional

Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

NCT06226610
View directory record Official record
Conditions
Pruritis
Interventions
Dupilumab, Placebo
Drug · Other
Lead sponsor
Akron Children's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 21, 2026, 2:22 PM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

NCT04210843
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Not applicable Interventional

Bleach Bath Treatment of Adults With Atopic Dermatitis

NCT01996150
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
bleach bath (sodium hypochlorite)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 21, 2026, 2:22 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768
View directory record Official record
Conditions
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Interventions
Maralixibat, Placebo
Drug · Other
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 21, 2026, 2:22 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome

NCT01625455
View directory record Official record
Conditions
Sezary Syndrome, Pruritus
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli

NCT05287724
View directory record Official record
Conditions
Pruritus, Skin Disorder
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

NCT03816891
View directory record Official record
Conditions
Prurigo Nodularis, Pruritis
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

NCT05936567
View directory record Official record
Conditions
Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 21, 2026, 2:22 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

NCT04612725
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Benralizumab, Placebo and Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

NCT04823130
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Dupilumab (SAR231893)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)

NCT00509275
View directory record Official record
Conditions
Tinea Pedis
Interventions
W0027, Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Louisville, Kentucky • Warren, Michigan • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 21, 2026, 2:22 PM EDT
Completed No phase listed Observational

SOOTHER Trial to Treat Rectal Itch

NCT05288907
View directory record Official record
Conditions
Pruritus Ani
Interventions
Lidocaine Ointment
Drug
Lead sponsor
Bell International Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Plymouth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 21, 2026, 2:22 PM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

NCT05024058
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Ligelizumab, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Evansville, Indiana • North Charleston, South Carolina • El Paso, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of an Oral Supplement in Supporting Vision and Eye Health

NCT07123584
View directory record Official record
Conditions
Dry Eye, Eye Fatigue
Interventions
Eye Empower, Placebo
Dietary Supplement
Lead sponsor
Bio Nature Health
Industry
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of Econazole Foam 1% in Athlete's Foot

NCT00768599
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
Econazole Nitrate Cream 1%, Econazole Nitrate Foam 1%, Vehicle Foam
Drug
Lead sponsor
AmDerma
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
San Diego, California • Clinton Township, Michigan • Fridley, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function

NCT02268448
View directory record Official record
Conditions
Cutaneous Nerves CNS Itch
Interventions
Clonidine, Naltrexone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 21, 2026, 2:22 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section

NCT06297499
View directory record Official record
Conditions
Pruritus Caused by Drug
Interventions
Ondansetron 8mg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 21, 2026, 2:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®

NCT00275795
View directory record Official record
Conditions
Food Sensitivities, Headache, Backache, Indigestion, Eczema, Acne, Hives and Itching of the Skin
Interventions
NAET Procedures
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
2 Years to 78 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2006 · Synced Sep 21, 2026, 2:22 PM EDT
Active, not recruiting Phase 4 Interventional

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

NCT07006792
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 21, 2026, 2:22 PM EDT
Active, not recruiting Phase 2 Interventional

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

NCT07074977
View directory record Official record
Conditions
Chronic Pruritus of Unknown Origin
Interventions
nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Fountain Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 21, 2026, 2:22 PM EDT
Completed Not applicable Interventional Results available

The CO2RE® System for Vulvar Lichen Sclerosus

NCT04148651
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
The CO2RE® System
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Jacksonville, Florida • Cincinnati, Ohio • South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 21, 2026, 2:22 PM EDT